• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • CMDE Preps for AI Software to Soar in China

CMDE Preps for AI Software to Soar in China

Tuesday, 24 November 2020 / Published in Medical Device, News, NMPA Registration in China

CMDE Preps for AI Software to Soar in China

On October 30, the CMDE (Center for Medical Device Evaluation) of NMPA (National Medical Products Administration) announced their plan to draft the clinical evaluation and performance evaluation guidelines for AI software in diagnostic pathology. Both clinical evaluation and performance evaluation are part of the reviewing process of the product registrations in China.

According to the China’s Five-Year Plans and Made in China 2025, the development goals covered imaging equipment, AI robotics, wearables, remote diagnosis and treatment, etc. Based on reports from the NMPA, the medical imaging equipment currently takes up to 16% of the entire China medical device market. Also, 80% of the registered medical imaging equipment in China are supplied by foreign manufacturers. In January 2020, the DEEPVESSEL FFR was the first AI medical imaging equipment to be registered in China via the fast-track approval procedure.

Under the influence of China’s strategic policies, the AI medical imaging industry is expected to have a subsequent growth in China, and the outlook remains positive for importing AI software products with its current significant market share.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: AI medical devices, five-year plan, medical imaging equipment, SaMD, Software as Medical Device

What you can read next

China Implements Easier Transition for Localization of Overseas Manufacturers
Public Consultation on Overseas Inspection for Cosmetics
china cosmetics quality and safety
China Cosmetics Quality and Safety Manager Qualification Requirements Eased by NMPA

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP